Anti-Modified Protein Antibodies in Rheumatoid Arthritis: Pathogenic, Protective, or Passive Bystander?

Area of Science:

• Immunology
• Rheumatology
• Autoimmunity

Background:

• Anti-modified protein antibodies (AMPA) are characteristic of rheumatoid arthritis (RA).
• AMPA, including anti-citrullinated protein antibodies (ACPA), anti-carbamylated protein antibodies (anti-CarP), and anti-acetylated protein antibodies (AAPA), recognize post-translationally modified proteins.
• These autoantibodies can precede RA onset and are linked to disease development, progression, and risk factors like HLA alleles, smoking, and microbial exposure.

Purpose of the Study:

• To explore the multifaceted roles of AMPA in rheumatoid arthritis (RA) pathogenesis.
• To investigate the potential pathogenic and protective mechanisms of AMPA, particularly ACPA.
• To highlight the need for further research into AMPA characteristics and their functional impact in RA.

Main Methods:

• Review and synthesis of existing literature on AMPA in RA.
• Analysis of proposed mechanisms for ACPA-mediated pathogenesis (e.g., immune complex formation, Fc gamma receptor binding, complement activation, NET formation).
• Examination of proposed protective roles of ACPA (e.g., NET inhibition/clearance, Fc gamma receptor binding).

Main Results:

• AMPA are implicated in RA pathogenesis but their exact role is unclear.
• ACPA may promote inflammation and bone loss through various mechanisms.
• Conversely, ACPA might also offer protective effects by modulating NET formation and Fc gamma receptor interactions.
• Some ACPA may lack significant functional activity.

Conclusions:

• AMPA exhibit diverse functions in RA, encompassing both pathogenic and protective effects.
• Understanding the specific characteristics and mechanisms of AMPA is crucial for elucidating their role in RA.
• Further research is needed to fully comprehend the complex involvement of AMPA in rheumatoid arthritis.